Genomic landscape: mutational profile differences in baseline and on-treatment lesions in responder (R) vs. non-responder (NR) patients
tumor
TUMOR
Longitudinal multi-omics profiling, including whole exome sequencing (WES), RNA Sequencing (RNASeq), and Reduced representation bisulfite sequencing (RRBS), were performed on tumor biopsies collected at baseline (week 0) and week 4 and week 12 on therapy from 14 patients (Supplementary Fig 